Sugi Predict

Sugi Predict / Compounds / SCHEMBL203308

SCHEMBL203308

SCHEMBL203308

CC(C)(C)OC(=O)N1C[C@H](O)[C@H](O)[C@H]1C(=O)NOCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ GHSR Q92847 5/20 0.41
▸ STS P08842 1/20 0.41
▸ PARP1 P09874 1/20 0.39
▸ KLK7 P49862 1/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ CTSL P07711 1/20 0.39
▸ HTRA1 Q92743 1/20 0.38
▸ ABCB1 P08183 1/20 0.38
▸ MMP3 P08254 2/20 0.38
▸ MMP9 P14780 2/20 0.38
▸ ADAM17 P78536 2/20 0.38
▸ MMP1 P03956 1/20 0.38
▸ NR1H2 P55055 2/20 0.38
▸ NR1H3 Q13133 2/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL203307 1.00 GHSR (0.41) GHSRSTSPARP1KLK7NPC1
SCHEMBL200777 0.85 NPC1 (0.44) NPC1RAB9ASMN1; SMN2MMP3MMP9
SCHEMBL13530902 0.84 GHSR (0.37) GHSRSTSPARP1KLK7NPC1
SCHEMBL8279010 0.83 CTSL (0.49) PARP1KLK7CTSLABCB1NR1H2
SCHEMBL201376 0.83 KLK7 (0.42) GHSRSTSPARP1KLK7NPC1
SCHEMBL201375 0.83 KLK7 (0.42) GHSRSTSPARP1KLK7NPC1
SCHEMBL201456 0.83 KLK7 (0.42) GHSRSTSPARP1KLK7NPC1
SCHEMBL2693205 0.83 KLK7 (0.42) GHSRSTSPARP1KLK7NPC1
SCHEMBL3546934 0.79 MEN1 (0.50) GHSRSTSKLK7NPC1RAB9A
SCHEMBL3546930 0.79 MEN1 (0.50) GHSRSTSKLK7NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 — — US disclosed
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 — — US disclosed
EP-2338878-A2 N-hydroxyamide derivatives possessing antibacterial activity Vicuron Pharmaceuticals, Inc. (US) 2011-06-29 — — EP disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 — — US disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 — — US disclosed
EP-1963262-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2008-09-03 — — EP disclosed
WO-2007069020-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-06-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY NAAA, HDHD5, HACL2 GHSR 1457/4885STS 624/4885PARP1 2363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.